Poly-ADP-Ribose-Polymerase inhibition ameliorates hind limb ischemia reperfusion injury in a murine model of type 2 diabetes

Annals of Surgery

Volumn 258, Issue 6, 2013, Pages 1087-1095

  Long, Chandler A ^a,b,c   Boloum, Valy ^a,d   Albadawi, Hassan ^a   Tsai, Shirling ^a   Yoo, Hyung Jin ^a   Oklu, Rahmi ^a,b   Goldman, Mitchell H ^b   Watkins, Michael T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

^c UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^d SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

diabetes; ischemia; reperfusion; skeletal muscle

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RINGER LACTATE SOLUTION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG HALF LIFE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE TRANSLOCATION; INFLAMMATION; LIMB ISCHEMIA; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE (NADP+); HINDLIMB; MALE; MICE; POLY(ADP-RIBOSE) POLYMERASES; REPERFUSION INJURY;

EID: 84888137780     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31828cced3     Document Type: Article

References (53)

1. Green LW, Brancati FL, Albright A. Primary prevention of type 2 diabetes: integrative public health and primary care opportunities, challenges and strategies. Fam Pract. 2012;29(suppl 1):i13-i23.
2. Raman R, Gupta A, Krishna S, et al. Prevalence and risk factors for diabetic microvascular complications in newly diagnosed type II diabetes mellitus. Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS, report 27). J Diabetes Complications. 2012;26:123-8.
3. Granger DN, Rodrigues SF, Yildirim A, et al. Microvascular responses to cardiovascular risk factors. Microcirculation. 2010;17:192-205.
4. Horvath EM, Magenheim R, Kugler E, et al. Nitrative stress and poly(ADPribose) polymerase activation in healthy and gestational diabetic pregnancies. Diabetologia. 2009;52:1935-1943.
5. Kiss L, Szabo C. The pathogenesis of diabetic complications: the role of DNA injury and poly(ADP-ribose) polymerase activation in peroxynitrite-mediated cytotoxicity. Mem Inst Oswaldo Cruz. 2005;100(suppl 1):29-37.
6. Shrikhande G, Khaodhiar L, Scali S, et al.Valsartan improves resting skin blood flowin type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation. J Vasc Surg. 2006;43:760-770; discussion 770-771.
7. Sodhi RK, Singh N, Jaggi AS. Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications. Vascul Pharmacol. 2010;53:77-87.
8. Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Ann Oncol. 2010;22:268-279.
9. Adaikalakoteswari A, Rema M, Mohan V, et al. Oxidative DNA damage and augmentation of poly(ADP-ribose) polymerase/nuclear factor-kappa B signaling in patients with type 2 diabetes and microangiopathy. Int J Biochem Cell Biol. 2007;39:1673-1684.
10. Pacher P, Szabo C. Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid Redox Signal. 2005;7:1568-1580.
11. Szabo C. PARP as a drug target for the therapy of diabetic cardiovascular dysfunction. Drug News Perspect. 2002;15:197-205.
12. Devalaraja-Narashimha K, Padanilam BJ. PARP-1 inhibits glycolysis in ischemic kidneys. J Am Soc Nephrol. 2009;20:95-103.
13. Du X, Matsumura T, Edelstein D, et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates threemajor pathways of hyperglycemic damage in endothelial cells. J Clin Invest. 2003;112:1049-1057.
14. Kawaji T, Elner VM, Yang DL, et al. Ischemia-induced nitrotyrosine formation and nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase in human retinal pigment epithelium in vivo. Redox Rep. 2011;16:24-26.
15. Tanaka R, Mochizuki H, Suzuki A, et al. Induction of glyceraldehyde-3- phosphate dehydrogenase (GAPDH) expression in rat brain after focal ischemia/reperfusion. J Cereb Blood Flow Metab. 2002;22:280-288.
16. Conrad MF, Stone DH, Albadawi H, et al. Local inflammatory and thrombotic responses differ in a murine model of partial and complete hindlimb ischemia/reperfusion. Surgery. 2005;138:375-381.
17. Crawford RS, Albadawi H, Atkins MD, et al. Postischemic poly (ADP-ribose) polymerase (PARP) inhibition reduces ischemia reperfusion injury in a hindlimb ischemia model. Surgery. 2010;148:110-118.
18. Crawford RS, Hashmi FF, Jones JE, et al. A novel model of acute murine hindlimb ischemia. Am J Physiol Heart Circ Physiol. 2007;292:H830-H837.
19. Conrad MF, Albadawi H, Stone DH, et al. Local administration of the Poly ADP-Ribose Polymerase (PARP) inhibitor, PJ34 during hindlimb ischemia modulates skeletal muscle reperfusion injury. J Surg Res. 2006;135:233-237.
20. Mustoe TA, O'Shaughnessy K, Kloeters O. Chronic wound pathogenesis and current treatment strategies: a unifying hypothesis. Plast Reconstr Surg. 2006;117:35S-41S.
21. Saito Y, Hasegawa M, Fujimoto M, et al. The loss of MCP-1 attenuates cutaneous ischemia-reperfusion injury in a mouse model of pressure ulcer. J Invest Dermatol. 2008;128:1838-1851.
22. Tsuji S, Ichioka S, Sekiya N, et al. Analysis of ischemia-reperfusion injury in a microcirculatory model of pressure ulcers.Wound Repair Regen. 2005;13:209-215.
23. Bonheur JA, Albadawi H, Patton GM, et al. A noninvasive murine model of hind limb ischemia-reperfusion injury. J Surg Res. 2004;116:55-63.
24. Jagtap P, Soriano FG, Virag L, et al. Novel phenanthridinone inhibitors of poly (adenosine 5'-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Crit Care Med. 2002;30:1071-1082.
25. Mabley JG, Jagtap P, Perretti M, et al. Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase. Inflamm Res. 2001;50:561-569.
26. Pacher P, Mabley JG, Soriano FG, et al. Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging. Int J Mol Med. 2002;9:659-664.
27. McCormack MC, Kwon E, Eberlin KR, et al. Development of reproducible histologic injury severity scores: skeletal muscle reperfusion injury. Surgery. 2008;143:126-133.
28. Crawford RS, Albadawi H, Atkins MD, et al. Postischemic treatment with ethyl pyruvate prevents adenosine triphosphate depletion, ameliorates inflammation, and decreases thrombosis in a murine model of hind-limb ischemia and reperfusion. J Trauma. 2011;70:103-110; discussion 110.
29. Abbruzzese TA, Albadawi H, Kang J, et al. Enoxaparin does not ameliorate limb ischemia-reperfusion injury. J Surg Res. 2008;147:260-266.
30. Bhatwadekar AD, Guerin EP, Jarajapu YP, et al. Transient inhibition of transforming growth factor-beta1 in human diabetic CD34+cells enhances vascular reparative functions. Diabetes. 2010;59:2010-2019.
31. Jushinskis J, Trushkov S, Bicans J, et al. Risk factors for the development of delayed graft function in deceased donor renal transplants. Transplant Proc. 2009;41:746-748.
32. Peralta-Leal A, Rodriguez-Vargas JM, Aguilar-Quesada R, et al. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radic Biol Med. 2009;47:13-26.
33. Traustadottir T, Davies SS, Stock AA, et al. Tart cherry juice decreases oxidative stress in healthy older men and women. J Nutr. 2009;139:1896-1900.
34. Hua HT, Albadawi H, Entabi F, et al. Polyadenosine diphosphate-ribose polymerase inhibition modulates skeletal muscle injury following ischemia reperfusion. Arch Surg. 2005;140:344-351; discussion 351-352.
35. La Bonte LR, Davis-Gorman G, StahlGL, et al.Complement inhibition reduces injury in the type 2 diabetic heart following ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2008;294:H1282-H1290.
36. Thakker GD, Frangogiannis NG, BujakM, et al. Effects of diet-induced obesity on inflammation and remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;291:H2504-H2514.
37. Gabr M, Hussein A, Sherif I, et al. Renal ischemia/reperfusion injury in type II DM: possible role of proinflammatory cytokines, apoptosis, and nitric oxide. J Physiol Pathophysiology. 2011;2:6-17.
38. McCall CE, Yoza B, Liu T, et al. Gene-specific epigenetic regulation in serious infections with systemic inflammation. J Innate Immun. 2010;2:395-405.
39. Dwivedi RS, Herman JG, McCaffrey TA, et al. Beyond genetics: epigenetic code in chronic kidney disease. Kidney Int. 2011;79:23-32.
40. Ao L, Zou N, Cleveland JC, Jr, et al. Myocardial TLR4 is a determinant of neutrophil infiltration after global myocardial ischemia: mediating KC and MCP-1 expression induced by extracellular HSC70. Am J Physiol Heart Circ Physiol. 2009;297:H21-H28.
41. Maheshwari A, Christensen RD, Calhoun DA, et al. Circulating CXCchemokine concentrations in a murine intestinal ischemia-reperfusion model. Fetal Pediatr Pathol. 2004;23:145-157.
42. Kirk G, Hickman P, McLaren M, et al. Interleukin-8 (IL-8) may contribute to the activation of neutrophils in patients with peripheral arterial occlusive disease (PAOD). Eur J Vasc Endovasc Surg. 1999;18: 434-438.
43. Huda R, Solanki DR, Mathru M. Inflammatory and redox responses to ischaemia/reperfusion in human skeletal muscle. Clin Sci (Lond). 2004;107: 497-503.
44. Andreozzi GM,Martini R, Cordova R, et al. Circulating levels of cytokines (IL-6 and IL-1beta) in patients with intermittent claudication, at rest, after maximal exercise treadmill test and during restore phase. Could they be progression markers of the disease? Int Angiol. 2007;26:245-252.
45. McDermott MM, Liu K, Ferrucci L, et al. Circulating blood markers and functional impairment in peripheral arterial disease. J Am Geriatr Soc. 2008;56:1504-1510.
46. Palmer-Kazen U, Religa P, Wahlberg E. Exercise in patients with intermittent claudication elicits signs of inflammation and angiogenesis. Eur J Vasc Endovasc Surg. 2009;38:689-696.
47. Unal O, Karatepe O, Ugurlucan M, et al. Effects of lower extremity revascularization on the endothelial functions measured with noninvasive brachial artery flow-mediated dilatation. Ann Vasc Surg. 2011;25:969-974.
48. Cottart CH, Nivet-Antoine V, Do L, et al. Hepatic cytoprotection by nitric oxide and the cGMP pathway after ischaemia-reperfusion in the rat. Nitric Oxide. 2003;9:57-63.
49. Sappington RM, Chan M, Calkins DJ. Interleukin-6 protects retinal ganglion cells from pressure-induced death. Invest Ophthalmol Vis Sci. 2006;47:2932-2942.
50. Terui K, Enosawa S, Haga S, et al. Stat3 confers resistance against hypoxia/reoxygenation-induced oxidative injury in hepatocytes through upregulation of Mn-SOD. J Hepatol. 2004;41:957-965.
51. Sukhanov S, Higashi Y, Shai SY, et al. Novel effect of oxidized low-density lipoprotein: cellular ATP depletion via downregulation of glyceraldehyde-3-phosphate dehydrogenase. Circ Res. 2006;99:191-200.
52. Kubis HP, Hanke N, Scheibe RJ, et al. Accumulation and nuclear import of HIF1 alpha during high and low oxygen concentration in skeletal muscle cells in primary culture. Biochim Biophys Acta. 2005;1745:187-195.
53. Meissner JD, Gros G, Scheibe RJ, et al. Calcineurin regulates slow myosin, but not fast myosin or metabolic enzymes, during fast-to-slow transformation in rabbit skeletal muscle cell culture. J Physiol. 2001;533(pt 1):215-226.